Patrick Boland, MD
Medical Oncology · New Brunswick, NJNPI 1982870333
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $20,271 of the $28,638 with a category attached, or 70.8%. It is spread thinly across 14 manufacturers, the largest accounting for just 16.6%. 2025 is the largest year on record at $9,547, more than ten times the $351 reported in 2019.
Across 39 payments — averaging $734.31 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$5K
- Syndax Pharmaceuticals, Inc.$5K
- Incyte Corporation$5K
- Beigene USA, Inc.$4K
- Array Biopharma Inc$4K
- Taiho Oncology, Inc.$2K
- plus $5K from 8 others
Across 34 payments — averaging $38,281 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Merck$1.1M
- Janssen Research & Development, LLC$101K
- Macrogenics, Inc.$30K
- Ipsen Bioscience Inc.$23K
- AbbVie$15K
What the payments were for
- Consulting fees$20,27171%
- Speaking & faculty fees$3,60013%
- Travel & lodging$3,43812%
- Food & beverage$1,3295%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 6 | $4,766 |
| Syndax Pharmaceuticals, Inc. | 6 | $4,735 |
| Incyte Corporation | 7 | $4,682 |
| Beigene USA, Inc. | 4 | $4,017 |
| Array Biopharma Inc | 2 | $3,600 |
| Taiho Oncology, Inc. | 1 | $2,200 |
| Merck | 2 | $1,865 |
| Seagen Inc. | 1 | $1,375 |
| Bayer | 3 | $956 |
| Bristol Myers Squibb | 1 | $127 |
| Genentech USA, Inc. | 2 | $114 |
| Ipsen Biopharmaceuticals, Inc | 1 | $110 |
| AstraZeneca | 2 | $62 |
| GSK | 1 | $30 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$28,638 in reported general payments places this provider in the 80th percentile of 112 medical oncology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 11 | $8,671 |
| Imatinib Mesylate | 18 | $3,947 |
| Prochlorperazine Maleate | 18 | $240 |
| Oxycodone Hcl | 19 | $228 |
| Ondansetron Hcl | 25 | $216 |
| Pantoprazole Sodium | 17 | $138 |
| Levothyroxine Sodium | 21 | $120 |
| Trazodone Hcl | 14 | $41 |
| Amlodipine Besylate | 13 | $10 |
Paid to pharmacies, not to this prescriber.
Other medical oncology in New Brunswick
- Kristen SpencerNew Brunswick$50K
- Sarah WeissNew Brunswick$30K
- Missak HaigentzNew Brunswick$30K
- Shridar GanesanNew Brunswick$27K
- Roman GroisbergNew Brunswick$22K
- Deborah ToppmeyerNew Brunswick$21K
- Morana VojnicNew Brunswick$16K
- Sanjay GoelNew Brunswick$13K
- Tina MayerNew Brunswick$10K
- Joseph AisnerNew Brunswick$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.